Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
A Supportive Membership Offer While You Plan Your Next Step
Being made redundant, or finding yourself between roles for any reason, can be an unsettling time. It can also be an important moment to reconnect with your professional community, explore new opportunities, and invest in your next step.
New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact.
DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.
Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa solutions, has moved into Colworth Science Park’s food tech incubator Gastronomica.
Gastronomica is a home for ambitious food-tech businesses advancing the future of food, enabling innovators and industry leaders to scale ideas, tackle global food shortages, and drive sustainable solutions.
📣 Join HBA Cambridge and Deloitte for 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐚 𝐇𝐞𝐚𝐥𝐭𝐡𝐢𝐞𝐫 𝐅𝐮𝐭𝐮𝐫𝐞 on 30 September.
This event will explore how a prevention-first approach can improve health outcomes, reduce health inequalities, strengthen healthcare sustainability, and keep the patient voice at the heart of innovation.
Hear from leaders across healthcare, life sciences, public health, and patient advocacy, with the discussion moderated by Elizabeth Hampson, UK Life Sciences and Health Innovation Partner at Deloitte.
Beacon for rare diseases, a Cambridge-based charity, has just launched Rare Insights – a ground-breaking study exploring the value and impact of rare disease patient groups, alongside the challenges they face.
Patient groups are often the first port-of-call for newly diagnosed patients with a rare disease. By providing much-needed support to individuals with rare diseases and their families, they become a lifeline, frequently advocating for research and helping to shape policies that put patients at their heart.
How do you drug the undruggable?
This is the question Jon Heal, EVP In Silico at RxCelerate, will tackle in our upcoming webinar, exploring how hidden binding sites can be uncovered in challenging drug targets.
Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.
Established in 2005, Boyds provides specialist consultancy services to an international client base, supporting the development of new, cutting-edge medicines and medical devices for patient benefit.
The post holder is expected to provide expertise and support in:
The candidate will also have access to training opportunities within the Norwich Research Park and the collaborative network to develop their laboratory and analytical skills.